William R. Gillespie, Ph.D.

Vice President, Strategic Modeling and Simulation

For over 20 years Bill has been involved in the development and application of pharmacometric methodology for enhancing drug treatment, development and regulation. His current interests include the use of Bayesian modeling and simulation to optimize decision-making in clinical drug development and treatment. He plans to make Bayesian modeling and simulation methods more accessible via training programs and development of software tools.

Recent publications by this scientist

A model of fracture risk used to examine the link between bone mineral density and the impact of different therapeutic mechanisms on fracture outcomes in patients with osteoporosis

November 3, 2017

Eudy-Byrne RJ, Gillespie W, Riggs MM. Gastonguay MR. J Pharmacokinet Pharmacodyn (2017).  First online 28 Oct 2017. https://doi.org/10.1007/s10928-017-9551-z

Download PDF

Gaining efficiency by combining analytical and numerical methods to solve ODEs: Implementation in Stan and application to Bayesian PK/PD modeling

October 17, 2017

Margossian C and Gillespie WR.  Presented at the 8th American Conference on Pharmacometrics (ACoP), Fort Lauderdale, FL, October 2017.

Download PDF

Stan functions for Bayesian pharmacometric modeling

October 1, 2016

Margossian CC and Gillespie WR.  Presented at the 7th American Conference on Pharmacometrics (ACoP), Bellevue, WA; October 2016.

Download PDF